Comprehensive Circulatory Metabolomics in ME/CFS Reveals Disrupted Metabolism of Acyl Lipids and Steroids.
Germain, Arnaud, Barupal, Dinesh K, Levine, Susan M et al. · Metabolites · 2020 · DOI
Quick Summary
Researchers studied the chemicals in blood samples from 26 ME/CFS patients and 26 healthy controls to understand what might be different in ME/CFS. They found that ME/CFS patients have lower levels of certain fats (especially acyl cholines) and hormones (including some involved in stress response and reproduction) compared to healthy people. These chemical differences might help explain why ME/CFS causes such widespread symptoms affecting many body systems.
Why It Matters
This study provides objective biological markers that could help validate ME/CFS as a physiological condition and advance understanding of its multi-system effects. The findings on reduced acyl cholines and steroid hormones offer new targets for investigating disease mechanisms and potentially developing treatments.
Observed Findings
All acyl choline compounds were consistently reduced in ME/CFS patients across two independent cohorts
Androgenic, progestin, and corticosteroid levels were broadly reduced in the patient group
Sphingolipid abundance was elevated in ME/CFS patients compared to controls
Dipeptide levels were lower in ME/CFS patients
About 1,750 blood compounds were analyzed across multiple metabolic pathways, revealing widespread metabolic disruptions
Inferred Conclusions
Acyl cholines represent a promising biomarker class for ME/CFS and may contribute to understanding the disease's multi-system symptoms
Broad disruption of steroid metabolism could underlie the profound effects of ME/CFS on multiple organ systems
Metabolomics can identify objective biological signatures in ME/CFS that differentiate patients from healthy controls
Disrupted lipid metabolism is a central feature of ME/CFS pathophysiology
Remaining Questions
Do the reduced acyl cholines and steroid hormones cause ME/CFS symptoms, or are they consequences of the disease process?
What This Study Does Not Prove
This study does not prove that the identified metabolic changes cause ME/CFS symptoms—they may be consequences of the illness or indirect markers. The cross-sectional design cannot establish temporal relationships or determine whether these changes are specific to ME/CFS or correlate with severity. Results are limited to women and require validation in larger, more diverse populations.